Francisco Oliveira

Has grant

Researcher

Champalimaud Foundation
Country flagPortugal

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

LyRaCAD: CAD system for analysis of PET/CT images with FDG in lymphomas - a radiomics approach

Open Date: 2019-01-01

Close Date: 2022-01-01

Grant: Close

Cognition and brain amyloid deposition in transthyretin-related familial amyloid polyneuropathy

Open Date: 2018-01-01

Close Date:

Grant: Close

BTSCAD: Bone Tumor Scan - CAD

Open Date: 2017-02-07

Close Date: 2019-11-30

Grant: Close

Distress and regional brain metabolism: a correlational study in metastatic breast cancer patients

Open Date: 2017-01-01

Close Date: 2021-01-01

Grant: Close

Quantificação em PET: construção de um sistema distribuído não-invasivo para medida da função de entrada arterial

Open Date: 2016-07-01

Close Date: 2018-06-30

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Purpose Advancements of deep learning in medical imaging are often constrained by the limited availability of large, annotated datasets, resulting in underperforming models when deployed under real-world conditions. This study investigated a generative artificial intelligence (AI) approach to create synthetic medical images taking the example of bone scintigraphy scans, to increase the data diversity of small-scale datasets for more effective model training and improved generalization. Methods We trained a generative model on 99m Tc-bone scintigraphy scans from 9,170 patients in one center to generate high-quality and fully anonymized annotated scans of patients representing two distinct disease patterns: abnormal uptake indicative of (i) bone metastases and (ii) cardiac uptake indicative of cardiac amyloidosis. A blinded reader study was performed to assess the clinical validity and quality of the generated data. We investigated the added value of the generated data by augmenting an independent small single-center dataset with synthetic data and by training a deep learning model to detect abnormal uptake in a downstream classification task. We tested this model on 7,472 scans from 6,448 patients across four external sites in a cross-tracer and cross-scanner setting and associated the resulting model predictions with clinical outcomes. Results The clinical value and high quality of the synthetic imaging data were confirmed by four readers, who were unable to distinguish synthetic scans from real scans (average accuracy: 0.48% [95% CI 0.46–0.51]), disagreeing in 239 (60%) of 400 cases (Fleiss’ kappa: 0.18). Adding synthetic data to the training set improved model performance by a mean (± SD) of 33(± 10)% AUC ( p < 0.0001) for detecting abnormal uptake indicative of bone metastases and by 5(± 4)% AUC ( p < 0.0001) for detecting uptake indicative of cardiac amyloidosis across both internal and external testing cohorts, compared to models without synthetic training data. Patients with predicted abnormal uptake had adverse clinical outcomes (log-rank: p < 0.0001). Conclusions Generative AI enables the targeted generation of bone scintigraphy images representing different clinical conditions. Our findings point to the potential of synthetic data to overcome challenges in data sharing and in developing reliable and prognostic deep learning models in data-limited environments. Graphical abstract

Year:

2025

Benefits in patient comfort, efficiency, and sustainability can come from reducing positron emission tomography (PET) scan’s acquisition duration. This study assesses the clinical adequacy of restoring fast-acquisition 18 F-fluorodeoxyglucose ([ 18 F]FDG) PET to its standard-of-care image quality through deep-learning-based (DL) methods. Fast and standard whole-body [ 18 F]FDG PET acquisitions of 117 oncological patients were included in the training and testing of three convolutional neural networks. The best-performing network during training was chosen for clinical evaluation on the test set ( N = 25). Visual assessment and lesion detectability of the fast acquisitions, of 20 and 30 seconds per axial field of view (s/AFOV), with and without DL-based denoising, and of the local standard of care, of 70 s/AFOV, were performed by three experienced nuclear medicine physicians. Quantification was conducted globally (voxel-wise), in healthy organs and the reported lesions. Optimised Gaussian and non-local means filters served as benchmarks. Visual assessment revealed 20 and 30 s/AFOV with DL-based denoising to have similar image quality to the standard of care. Average lesion-based sensitivity and positive predictive value were 74% and 72%, respectively, for 20 s/AFOV + DL and 72% and 80% for 30 s/AFOV + DL. DL-based denoising displayed the highest voxel-wise agreement with the standard-of-care ( p < 0.001). Liver and lungs in the DL-denoised images exhibited a higher signal-to-noise ratio than the standard of care. The median absolute maximum standardised uptake value deviation in the lesions was as low as 0.39 for 20 s/AFOV + DL and 0.30 for 30 s/AFOV + DL. The proposed DL-based method proved to be suitable for the restoration of fast-acquisition whole-body [ 18 F]FDG PET, having resulted in images similar to the standard-of-care acquisitions. DL-based denoising outperformed standard benchmark methods.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Purpose To verify the ability of pretreatment [ 18 F]FDG PET/CT and T1-weighed dynamic contrast-enhanced MRI to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients. Methods This retrospective study includes patients with BC of no special type submitted to baseline [ 18 F]FDG PET/CT, NAC and surgery. [ 18 F]FDG PET-based features reflecting intensity and heterogeneity of tracer uptake were extracted from the primary BC and suspicious axillary lymph nodes (ALN), for comparative analysis related to NAC response (pCR vs. non-pCR). Multivariate logistic regression was performed for response prediction combining the breast tumor-extracted PET-based features and clinicopathological features. A subanalysis was performed in a patients’ subsample by adding breast tumor-extracted first-order MRI-based features to the multivariate logistic regression. Results A total of 170 tumors from 168 patients were included. pCR was observed in 60/170 tumors (20/107 luminal B-like, 25/45 triple-negative and 15/18 HER2-enriched surrogate molecular subtypes). Higher intensity and higher heterogeneity of [ 18 F]FDG uptake in the primary BC were associated with NAC response in HER2-negative tumors (immunohistochemistry score 0, 1 + or 2 + non-amplified by in situ hybridization). Also, higher intensity of tracer uptake was observed in ALN in the pCR group among HER2-negative tumors. No [ 18 F]FDG PET-based features were associated with pCR in the other subgroup analyses. A subsample of 103 tumors was also submitted to extraction of MRI-based features. When combined with clinicopathological features, neither [ 18 F]FDG PET nor MRI-based features had additional value for pCR prediction. The only significant predictors were estrogen receptor status, HER2 expression and grade. Conclusion Pretreatment [ 18 F]FDG PET-based features from primary BC and ALN are not associated with response to NAC, except in HER2-negative tumors. As compared with pathological features, no breast tumor-extracted PET or MRI-based feature improved response prediction.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (14)

Sofia Carrilho Vaz

Specialist in Nuclear Medicine

Champalimaud Foundation

PORTUGAL
View details

Joaquim Alves da Silva

Group Leader

Champalimaud Foundation

PORTUGAL
View details

Isabel Catarina Duarte

University of Coimbra

PORTUGAL
View details

Gabriela Ribeiro

Assistant Professor

Universidade do Porto Faculdade de Medicina

PORTUGAL
View details

Andrea DeCensi

Director

Champalimaud Foundation

PORTUGAL
View details

Luca Camoni

University of Brescia

ITALY
View details

Celeste Alves

Head of Breast Radiology

Champalimaud Foundation

PORTUGAL
View details

Joaquim Reis

Researcher

Instituto Piaget

PORTUGAL
View details

Ana Maia

Assistant Professor in Fundamental Neuroscience

Universidade Nova de Lisboa, NOVA Medical School | Faculdade de Ciências Médicas

PORTUGAL
View details

Jorge Manuel Trindade Rebola

Professor Auxiliar

Egas Moniz Cooperativa de Ensino Superior CRL

PORTUGAL
View details

Susana Vinga

Associate Professor

Universidade de Lisboa Instituto Superior Técnico

PORTUGAL
View details

Albino Jorge Oliveira-Maia

Universidade de Aveiro

PORTUGAL
View details

Carolina Moreno

University of Coimbra

PORTUGAL
View details

Marcin Kubeczko

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details